GOP Lawmakers Push FDA on Clinical Trial Diversity

The persistent underrepresentation of racial and ethnic minority groups in clinical trials has long been a critical concern within medical research and public health. This issue is not merely one of equitable access or social justice; it carries direct implications for patient safety and treatment efficacy. Drugs often exhibit different pharmacokinetic and pharmacodynamic profiles across diverse populations due to genetic variations, environmental factors, and socioeconomic determinants of health. When trials fail to include a representative sample, clinicians are left with incomplete data, making it difficult to predict how a drug will perform in all patients, particularly those from underrepresented backgrounds.

For decades, the FDA has acknowledged this problem, issuing guidance documents and recommendations aimed at improving diversity. The agency's 2020 guidance, for example, urged sponsors to develop Race and Ethnicity Diversity Plans for late-phase trials, outlining strategies for recruitment and retention. But these have largely remained recommendations, lacking the force of regulation. This is the crux of the current congressional push: a demand for the FDA to move beyond encouragement and implement concrete, enforceable measures to ensure trial populations mirror the diversity of the US population. The argument from lawmakers is that without such enforcement, health disparities will only widen, and the promise of precision medicine will remain unfulfilled for many.

The push for enforceable diversity

The recent congressional inquiry, spearheaded by Republican members of the House Energy and Commerce Committee, specifically targets the FDA's implementation of Section 3601 of the Food and Drug Omnibus Reform Act of 2022 (FDORA). This legislation, signed into law in December 2022, mandates that sponsors of Phase III and other pivotal clinical trials submit a diversity action plan to the FDA. The plan must include specific goals for enrolment of underrepresented populations, a rationale for those goals, and a strategy for achieving them. Crucially, FDORA also grants the FDA the authority to require amendments to these plans if they are deemed insufficient. This is a significant shift from previous guidance, providing the agency with a statutory lever to demand action.

Lawmakers are now pressing the FDA to articulate how it plans to use this new authority. They want to know what metrics the agency will employ to assess the adequacy of diversity plans, what constitutes an 'insufficient' plan, and what consequences sponsors will face if they fail to meet their diversity goals. The concern is that without clear enforcement mechanisms and transparent reporting, the new legislation could become another set of well-intentioned but ultimately ineffective guidelines. The letter from Congress highlights the need for the FDA to establish clear benchmarks for what constitutes 'adequate' representation, moving beyond vague aspirations to quantifiable targets for racial, ethnic, age, and sex diversity.

The historical data on trial diversity paints a stark picture. A review of pivotal trials supporting new drug approvals between 2007 and 2017 revealed that while Black or African American individuals constitute approximately 13% of the US population, they represented only 5% of trial participants. Hispanic or Latino individuals, comprising about 18% of the population, made up only 11% of trial participants. These disparities are even more pronounced in specific disease areas, such as oncology and cardiology, where certain minority groups bear a disproportionate disease burden. For example, Black patients experience higher rates of hypertension and heart failure, yet their representation in cardiovascular trials often lags. This means that when a new antihypertensive drug is approved, the data on its efficacy and safety in a significant portion of the patient population may be limited, forcing clinicians to extrapolate from less representative cohorts.

The challenges to achieving diversity are complex and multifaceted. They include historical mistrust of the medical establishment within certain communities, socioeconomic barriers such as lack of transportation or time off work, and systemic biases in recruitment practices. Clinical trial sites are often located in academic medical centres that may not be easily accessible to diverse populations. Furthermore, trial protocols can be overly restrictive, excluding patients with common comorbidities or those on multiple medications, which disproportionately affects older adults and minority groups. The congressional push implicitly acknowledges these systemic issues, demanding that the FDA not only review diversity plans but also actively work with sponsors to dismantle these barriers.

One proposed solution involves leveraging real-world data and decentralised trial designs. Real-world data, derived from electronic health records, insurance claims, and patient registries, can provide insights into drug performance in broader, more diverse populations post-approval. While not a substitute for prospective trial data, it can help identify disparities that were missed in the initial trials. Decentralised trials, which use remote monitoring, telemedicine, and local healthcare providers, can reduce the burden on participants, making it easier for individuals from underserved areas to enrol. The FDA has encouraged these approaches, but their widespread adoption and integration into diversity strategies remain inconsistent across the industry.

The FDA's response to the congressional inquiry will be critical. The agency must demonstrate a clear strategy for operationalising FDORA's mandates, including how it will review diversity plans, what criteria it will use for requiring amendments, and how it will track progress. Transparency in reporting diversity metrics across approved drugs will also be essential. Without public accountability, the risk remains that diversity plans become a bureaucratic checkbox rather than a genuine commitment to equitable research. The agency has a delicate balance to strike: enforcing diversity without unduly delaying drug development, a concern often raised by pharmaceutical companies. But the argument from public health advocates and now, increasingly, from lawmakers, is that the cost of inadequate diversity in terms of patient outcomes and health equity is simply too high to ignore.

The implications extend beyond drug approvals. Medical devices, diagnostics, and even digital health tools also require diverse testing to ensure their safety and effectiveness across all users. A pulse oximeter, for instance, may perform differently on individuals with darker skin tones, a disparity that became particularly evident during the COVID-19 pandemic. If the FDA's enforcement of diversity plans for drug trials proves effective, it could set a precedent for other regulated medical products, pushing the entire healthcare innovation ecosystem towards greater inclusivity. This is not just about meeting a quota; it is about generating scientifically sound data that serves all patients, ensuring that medical progress benefits everyone, not just a select few. The onus is now on the FDA to translate legislative intent into tangible, measurable improvements in clinical trial diversity.